vs
莫德纳（MRNA）与沃茨水工业（WTS）财务数据对比。点击上方公司名可切换其他公司
莫德纳的季度营收约是沃茨水工业的1.6倍（$1.0B vs $625.1M），沃茨水工业净利率更高（13.4% vs -19.7%，领先33.1%），沃茨水工业同比增速更快（15.7% vs -45.4%），沃茨水工业自由现金流更多（$140.3M vs $-880.0M），过去两年沃茨水工业的营收复合增速更高（4.6% vs -45.0%）
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
沃茨水工业旗下AERCO是暖通管道领域的商用冷凝锅炉、高效热水设备及能量回收系统供应商，服务覆盖教育、住宿、政府、办公楼、医疗、工业、多户型住宅等多元市场，1949年推出行业首款半即热式无罐蒸汽热水器，1988年推出首款冷凝全调制设备。
MRNA vs WTS — 直观对比
营收规模更大
MRNA
是对方的1.6倍
$625.1M
营收增速更快
WTS
高出61.1%
-45.4%
净利率更高
WTS
高出33.1%
-19.7%
自由现金流更多
WTS
多$1.0B
$-880.0M
两年增速更快
WTS
近两年复合增速
-45.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $625.1M |
| 净利润 | $-200.0M | $83.7M |
| 毛利率 | 79.6% | 49.5% |
| 营业利润率 | -25.6% | 18.2% |
| 净利率 | -19.7% | 13.4% |
| 营收同比 | -45.4% | 15.7% |
| 净利润同比 | -1638.5% | 24.0% |
| 每股收益（稀释后） | $-0.51 | $2.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MRNAWTS
| Q4 25 | — | $625.1M | ||
| Q3 25 | $1.0B | $611.7M | ||
| Q2 25 | — | $643.7M | ||
| Q1 25 | — | $558.0M | ||
| Q4 24 | $966.0M | $540.4M | ||
| Q3 24 | $1.9B | $543.6M | ||
| Q2 24 | — | $597.3M | ||
| Q1 24 | — | $570.9M |
净利润MRNAWTS
| Q4 25 | — | $83.7M | ||
| Q3 25 | $-200.0M | $82.2M | ||
| Q2 25 | — | $100.9M | ||
| Q1 25 | — | $74.0M | ||
| Q4 24 | $-1.1B | $67.5M | ||
| Q3 24 | $13.0M | $69.1M | ||
| Q2 24 | — | $82.0M | ||
| Q1 24 | — | $72.6M |
毛利率MRNAWTS
| Q4 25 | — | 49.5% | ||
| Q3 25 | 79.6% | 48.8% | ||
| Q2 25 | — | 50.6% | ||
| Q1 25 | — | 48.8% | ||
| Q4 24 | 23.5% | 46.7% | ||
| Q3 24 | 72.4% | 47.3% | ||
| Q2 24 | — | 47.7% | ||
| Q1 24 | — | 46.9% |
营业利润率MRNAWTS
| Q4 25 | — | 18.2% | ||
| Q3 25 | -25.6% | 18.2% | ||
| Q2 25 | — | 21.0% | ||
| Q1 25 | — | 15.7% | ||
| Q4 24 | -129.0% | 16.5% | ||
| Q3 24 | -3.8% | 17.1% | ||
| Q2 24 | — | 18.7% | ||
| Q1 24 | — | 16.9% |
净利率MRNAWTS
| Q4 25 | — | 13.4% | ||
| Q3 25 | -19.7% | 13.4% | ||
| Q2 25 | — | 15.7% | ||
| Q1 25 | — | 13.3% | ||
| Q4 24 | -115.9% | 12.5% | ||
| Q3 24 | 0.7% | 12.7% | ||
| Q2 24 | — | 13.7% | ||
| Q1 24 | — | 12.7% |
每股收益（稀释后）MRNAWTS
| Q4 25 | — | $2.50 | ||
| Q3 25 | $-0.51 | $2.45 | ||
| Q2 25 | — | $3.01 | ||
| Q1 25 | — | $2.21 | ||
| Q4 24 | $-2.91 | $2.02 | ||
| Q3 24 | $0.03 | $2.06 | ||
| Q2 24 | — | $2.44 | ||
| Q1 24 | — | $2.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $405.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.3B | $2.0B |
| 总资产 | $12.1B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MRNAWTS
| Q4 25 | — | $405.5M | ||
| Q3 25 | $1.1B | $457.7M | ||
| Q2 25 | — | $369.3M | ||
| Q1 25 | — | $336.8M | ||
| Q4 24 | $1.9B | $386.9M | ||
| Q3 24 | $1.6B | $303.9M | ||
| Q2 24 | — | $279.4M | ||
| Q1 24 | — | $237.1M |
股东权益MRNAWTS
| Q4 25 | — | $2.0B | ||
| Q3 25 | $9.3B | $2.0B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.8B | ||
| Q4 24 | $10.9B | $1.7B | ||
| Q3 24 | $11.9B | $1.7B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.6B |
总资产MRNAWTS
| Q4 25 | — | $2.9B | ||
| Q3 25 | $12.1B | $2.7B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | $14.1B | $2.4B | ||
| Q3 24 | $15.8B | $2.4B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-847.0M | $154.7M |
| 自由现金流经营现金流 - 资本支出 | $-880.0M | $140.3M |
| 自由现金流率自由现金流/营收 | -86.6% | 22.4% |
| 资本支出强度资本支出/营收 | 3.2% | 2.3% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-1.9B | $356.3M |
8季度趋势，按日历期对齐
经营现金流MRNAWTS
| Q4 25 | — | $154.7M | ||
| Q3 25 | $-847.0M | $122.4M | ||
| Q2 25 | — | $69.7M | ||
| Q1 25 | — | $55.2M | ||
| Q4 24 | $825.0M | $139.5M | ||
| Q3 24 | $-1.6B | $90.7M | ||
| Q2 24 | — | $85.3M | ||
| Q1 24 | — | $45.6M |
自由现金流MRNAWTS
| Q4 25 | — | $140.3M | ||
| Q3 25 | $-880.0M | $110.9M | ||
| Q2 25 | — | $59.5M | ||
| Q1 25 | — | $45.6M | ||
| Q4 24 | $303.0M | $127.5M | ||
| Q3 24 | $-1.7B | $84.3M | ||
| Q2 24 | — | $78.5M | ||
| Q1 24 | — | $35.5M |
自由现金流率MRNAWTS
| Q4 25 | — | 22.4% | ||
| Q3 25 | -86.6% | 18.1% | ||
| Q2 25 | — | 9.2% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | 31.4% | 23.6% | ||
| Q3 24 | -92.2% | 15.5% | ||
| Q2 24 | — | 13.1% | ||
| Q1 24 | — | 6.2% |
资本支出强度MRNAWTS
| Q4 25 | — | 2.3% | ||
| Q3 25 | 3.2% | 1.9% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | 54.0% | 2.2% | ||
| Q3 24 | 8.1% | 1.2% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.8% |
现金转化率MRNAWTS
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 1.49× | ||
| Q2 25 | — | 0.69× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 2.07× | ||
| Q3 24 | -120.46× | 1.31× | ||
| Q2 24 | — | 1.04× | ||
| Q1 24 | — | 0.63× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
WTS
暂无分部数据
